[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605554":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":76,"centralContacts":81,"locations":88,"responsibleParty":106,"collaborators":108,"id":112,"slug":113,"hasResults":114,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":86,"eligibilityCriteria":118,"healthyVolunteers":114,"sex":119,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":86,"studyType":125,"phases":126,"briefSummary":128,"conditions":129,"keywords":86,"overallStatus":90,"whyStopped":86,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},{"fullName":5,"class":6},"Jonsson Comprehensive Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Diagnostic (flotufolastat F-18 PET\u002FCT)","EXPERIMENTAL","Patients receive flotufolastat F-18 IV and then, 50-100 minutes later, undergo PET\u002FCT over 30 minutes. Within 6 months of PET\u002FCT imaging, patients undergo PSMA PET\u002FCT\u002FUS fusion biopsy and MRI\u002FUS fusion biopsy in a randomized order. Patients may undergo blood sample collection at screening and\u002For on study.",[13,14,15,16,17],"Procedure: Biopsy of Prostate","Procedure: Biospecimen Collection","Procedure: Computed Tomography","Radiation: Flotufolastat F-18 Gallium","Procedure: Positron Emission Tomography",[19,27,35,50,65],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"PROCEDURE","Biopsy of Prostate","Undergo biopsy",[9],[25,26],"Prostate Biopsy","Prostatic Biopsy",{"type":20,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Biospecimen Collection","Undergo collection of blood samples",[9],[32,33,34],"Biological Sample Collection","Biospecimen Collected","Specimen Collection",{"type":20,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"Computed Tomography","Undergo PET\u002FCT",[9],[40,41,42,43,44,45,46,47,48,49],"CAT","CAT Scan","Computed Axial Tomography","Computerized Axial Tomography","Computerized axial tomography (procedure)","Computerized Tomography","Computerized Tomography (CT) scan","CT","CT Scan","tomography",{"type":51,"name":52,"description":53,"armGroupLabels":54,"otherNames":55},"RADIATION","Flotufolastat F-18 Gallium","Given IV",[9],[56,57,58,59,60,61,62,63,64],"(18F)-rhPSMA-7.3","18F-rhPSMA-7.3","18FrhPSMA-7.3","F-18-rhPSMA-7.3","Fluorine F 18 Radiohybrid PSMA-7.3","Fluorine F 18 rhPSMA-7.3","Fluorine-18 rhPSMA-7.3","Posluma","rhPSMA-7.3 (18F)",{"type":20,"name":66,"description":37,"armGroupLabels":67,"otherNames":68},"Positron Emission Tomography",[9],[69,70,71,72,73,74,75],"Medical Imaging, Positron Emission Tomography","PET","PET Scan","Positron emission tomography (procedure)","Positron Emission Tomography Scan","Positron-Emission Tomography","PT",[77],{"name":78,"affiliation":79,"role":80},"Wayne Brisbane","UCLA \u002F Jonsson Comprehensive Cancer Center","PRINCIPAL_INVESTIGATOR",[82],{"name":83,"role":84,"phone":85,"phoneExt":86,"email":87},"Kyla Grunden","CONTACT","310-206-7576",null,"kgrunden@mednet.ucla.edu",[89],{"facility":79,"status":90,"city":91,"state":92,"zip":93,"country":94,"countryCode":95,"cosmosGeoPoint":96,"geoPoint":101,"contacts":102},"RECRUITING","Los Angeles","California","90095","United States","US",{"type":97,"coordinates":98},"Point",[99,100],-118.24368,34.05223,{"lat":100,"lon":99},[103,104],{"name":83,"role":84,"phone":85,"phoneExt":86,"email":87},{"name":105,"role":80,"phone":86,"phoneExt":86,"email":86},"Wayne Brisbane, MD",{"type":107,"investigatorFullName":86,"investigatorTitle":86,"investigatorAffiliation":86,"oldNameTitle":86,"oldOrganization":86},"SPONSOR",[109],{"name":110,"class":111},"Blue Earth Diagnostics","INDUSTRY","100605554","early-phase-1-comparing-a-new-psma-imaging-agent-to-mri-for-detecting-prostate-cancer-beacon-trial-100605554",false,"NCT07164027","Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial","Beacon: Prospective Assessment of Flotufolastat F 18 PSMA and MRI in the Diagnosis of Clinically Significant Prostate Cancer","Inclusion Criteria:\n\n* Men aged 18-90 at study enrollment\n* Have at least one PI-RADS 3-5 lesion on MRI within the 12 months prior to enrollment\n\nExclusion Criteria:\n\n* Contraindication to flotufolastat F 18 PET CT\n* Contraindication to ultrasound-guided prostate biopsy\n* Previous treatment of prostate cancer\n* Unable to discontinue blood thinners for 7 days prior to biopsy\n* Any investigational agents within 42 days prior to the day of the first dose\n* Not able to understand and to follow study instructions and requirements. This also includes the inability to complete the study imaging and or biopsy procedures due to any reason (e.g., severe claustrophobia, inability to lie still for the entire imaging time, any condition that precludes raised arms position)","MALE","18 Years","90 Years",{"count":123,"type":124},30,"ESTIMATED","INTERVENTIONAL",[127],"EARLY_PHASE1","This early phase I trial evaluates whether a new imaging technique using flotufolastat F 18 (a type of prostate specific membrane antigen \\[PSMA\\] imaging agent) with positron emission tomography (PET)\u002Fcomputed tomography (CT) can be used to guide targeted prostate biopsies in men with prostate cancer. Flotufolastat F 18 is a radioactive imaging agent that binds to prostate tumor cells that express PSMA. This allows for visualization of PSMA-expressing tumor cells on imaging scans such as PET\u002FCT. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, flotufolastat F 18. Because prostate cancer takes up flotufolastat F 18, it can be seen with PET. CT utilizes X-rays that track the body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in the body. The PET\u002FCT scanner combines the PET and the CT scanners into a single device. A targeted prostate biopsy refers to using advanced imaging for guidance when taking samples (biopsies) of the prostate. This method can fuse (combine) PET\u002FCT images with real-time ultrasound during a prostate biopsy. PSMA PET\u002FCT scans have the potential for guiding prostate biopsies. Using image fusion technology, they can increase detection of prostate cancer by providing anatomical information and guidance during a prostate biopsy. Improved detection of prostate cancer using PSMA PET\u002FCT guidance may better inform men and their clinicians about prostate cancer risk and management. This study attempts to determine how often prostate cancer is found when using PSMA PET\u002FCT scan images during a biopsy versus the conventional magnetic resonance imaging-guidance.",[130],"Prostate Carcinoma","2026-03-06",{"date":133,"type":134},"2026-03-10","ACTUAL",{"date":136,"type":134},"2025-11-14",{"date":138,"type":124},"2037-01-28",{"name":5,"class":6},1]